The recent FDA approval of three CDK4/6 inhibitors (CDK4/6is), palbociclib, ribociclib, and abemaciclib, has led to the rapid adoption of targeted treatment of CDK4/6 as first-line or second-line therapy in advanced ER + /HER2- breast cancer. This evidence concerns the gene ERBB2 and breast cancer.